Hexocyclium is a muscarinic acetylcholine receptor antagonist which was presumably used in the treatment of gastric ulcer or diarrhea. It was once available under the tradename Tral marketed by Abbvie... Proton pump inhibitors like DB00338 and opiate anti-diarrheal agents like DB00836 have largely replaced the use of anti-muscarinics in the treatment of gastric ulcers and diarrhea due to their more favorable side effect profiles.
- Mechanism
- Curator reviewed · 2 references
Hexocyclium binds to and inhibits muscarinic acetylcholine receptors. This decreases gastric acid secretion by preventing the activation of M3 receptors on pareital cells and subsequent stimulation of gastric acid secretion. The antagonism of M3 receptors in the intestine inhibits smooth muscle contraction resulting in a decrease in motility. The binding of hexocyclium to other muscarinic receptor types produces typical anti-muscarinic side effects.
- Primary indication
- The World Health Organization classifies hexocyclium as a drug for functional gastrointestinal disorders.Curator reviewed
- Formula / weight
- C20H33N2O · 317.496 g/mol (avg)
Resolves to
ZRYHPQCHHOKSMD-UHFFFAOYSA-NSMILESC[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1What you can answer from here — as of September 13, 2026
Which drugs share a target with Hexocyclium, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account